Sinomenine
Catalog No: CFN99508
Sinomenine shows neuroprotective, anti- rheumatoid arthritis, anti-inflammatory and immunosuppressive effects, it can attenuate 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice and the therapeutic mechanism may be related to the reduction of up-regulated colonic TNF-alpha and IFN-gamma production caused by TNBS. Sinomenine also provides a novel therapy to treat ICH induced brain injury. Sinomenine can prevent galactosamine (GalN)/lipopolysaccharide (LPS) -treated hepatic failure by suppressing TNF production and/or reactive oxygen generation.
Sodium Aescinate
Catalog No: CFN99509
Sodium aescinate has immunity enhancing,anti-inflammatory and antioxidant activities, may effectively control and improve wound healing in diabetic rats. It has obvious antiangiogenic effect, the initiation of angiogenesis and proliferation of endothelial cell are inhibited and the secretion of VEGF is also decreased. Sodium aescinate can protect the lung injury induced by intestinal ischemia/reperfusion (I/R), which may be mediated by inhibiting lipid peroxidation, upregulating Bcl-2 gene protein expression, improving the ratio of Bcl-2/ Bax to inhibit lung apoptosis.;it also can protect against liver injury induced by methyl parathion.
Norisoboldine
Catalog No: CFN99528
Norisoboldine produces anti-inflammatory and anti-rheumatoid arthritis effects, it produces the analgesic effect in inflammatory pain by a mechanism related to the adenosine system. Norisoboldine alleviated joint destruction in AIA rats by reducing RANKL, IL-6, PGE2, and MMP-13 expression via the p38/ERK/AKT/AP-1 pathway, it decreased forskolin-evoked cyclic adenosine monophosphate levels in mouse spinal cord neuronal cultures through the adenosine A1 receptor.